Psychiatric medication safety for the prescriber, at the moment of prescribing
40% of antidepressant patients discontinue within 90 days — mostly due to predictable side effects. Serotonin syndrome, QT prolongation, and CYP2D6/CYP2C19 polymorphism effects are clinically significant, well-documented, and systematically underaddressed at the point a Psychiatric Mental Health Nurse Practitioner writes a prescription.
Skippy Mind integrates psychiatric DDI checking, pharmacogenomics guidance, side effect profiling, and stepped-care protocol intelligence into a workflow tool built for how PMHNPs actually prescribe — not as an EHR plugin buried in a vendor roadmap.
PMHNPs manage complex polypharmacy with tools built for primary care
- ·General DDI checkers flag everything at the same severity — alert fatigue is the outcome, not safety
- ·Pharmacogenomics reports are static documents, not integrated at the prescribing moment
- ·Serotonin syndrome risk requires cumulative burden scoring across a patient's full regimen — no point-of-care tool does this
- ·QT prolongation risk from CredibleMeds requires manual cross-reference against the patient's current medications
- ·Side effect prediction doesn't account for patient age, BMI, or gene-drug pairs simultaneously
- ·Cumulative serotonin burden scoring across the patient's full medication panel — not just individual pairs
- ·CYP2D6 and CYP2C19 clinical action guidance integrated at the prescribing decision, not in a separate report
- ·CredibleMeds QT risk categories computed for any combination, with cumulative QTc impact
- ·Side effect prediction personalized by patient age, BMI, comorbidities, and confirmed gene-drug pairs
- ·Panel-level prioritization — surfaces which patients need attention most, for async workflow
The medication intelligence layer behavioral health is missing
Serotonin syndrome detection
Cumulative burden scoring across a patient's full medication panel — flagging high-risk combinations before the prescription is written, not after.
QT prolongation risk
CredibleMeds risk categories (Known/Conditional/Possible) integrated for every psychiatric drug combination, with cumulative QTc impact scoring.
Psychiatric pharmacogenomics
CYP2D6 and CYP2C19 gene-drug clinical action guidance for the most common psychiatric drug-gene pairs — AVOID / DOSE_REDUCE / MONITOR / NORMAL.
Side effect profile matching
Predicts most likely side effects for candidate psychiatric drugs given patient age, BMI, comorbidities, and current medications — ranked by frequency and mechanism.
Stepped-care protocol guidance
Evidence-based guidance from first-line to third-line selection, with side effect profiles and contraindications surfaced in patient context.
Panel-level prioritization
Identifies patients in a prescriber's panel where pharmacogenomics matters most — designed for async workflow integration, not alert fatigue.
Built for PMHNPs. Available to the platforms they use.
The primary target. PMHNPs are increasingly the front line of psychiatric prescribing — often without immediate physician supervision. 38–45K active prescribers in the US, with 35–40% workforce growth projected through 2030.
Telehealth and digital prescribing platforms serving behavioral health patients — where medication decisions happen at volume and the need for integrated safety intelligence is highest.
EHR platforms with psychiatry-specific workflows looking to add a medication intelligence layer that goes beyond standard DDI checking.
Early access for PMHNPs and prescribing platforms
We're working with PMHNPs and behavioral health platforms to shape the initial release. If you're a psychiatric prescriber or run a prescribing platform, we'd like to hear from you.